Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2009-04-09

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm801439xPMID 19271701PMCID PMC2666544
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.

  2009cited by this paper
• Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.

  2008cited by this paper
• Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor.

  2008cited by this paper
• Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting

  2008cited by this paper
• Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals.

  2008cited by this paper
• Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.

  2007cited by this paper
• Targeting CCK receptors in human cancers.

  2007cited by this paper
• Strategies for design of non peptide CCK1R agonist/antagonist ligands.

  2007cited by this paper
• Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma.

  2006cited by this paper
• Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

  2006cited by this paper
• Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.

  2006cited by this paper
• Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

  2005cited by this paper
• Differential Effects of Modification of Membrane Cholesterol and Sphingolipids on the Conformation, Function, and Trafficking of the G Protein-coupled Cholecystokinin Receptor*

  2005cited by this paper
• High expression of peptide receptors as a novel target in gastrointestinal stromal tumours

  2004cited by this paper
• Peptide receptors as molecular targets for cancer diagnosis and therapy.

  2003influential reference
• Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

  2003cited by this paper
• Heterodimerization of Type A and B Cholecystokinin Receptors Enhance Signaling and Promote Cell Growth*

  2003cited by this paper
• Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.

  2002cited by this paper
• Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy

  2002cited by this paper
• In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.

  2000cited by this paper
• Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.

  1999cited by this paper
• High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents.

  1999cited by this paper
• Synthesis and evaluation of 11C-labeled nonpeptide antagonists for cholecystokinin receptors: [11C]L-365,260 and [11C]L-365,346.

  1998cited by this paper
• A new convenient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for radioiodination of proteins

  1998cited by this paper
• Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor.

  1997cited by this paper
• Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach.

  1997cited by this paper
• Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.

  1997cited by this paper
• Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.

  1996cited by this paper
• Relationship Between Native and Recombinant Cholecystokinin Receptors: Role of Differential Glycosylation

  1996cited by this paper
• Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities.

  1996cited by this paper
• Multiple affinity states of different cholecystokinin receptors.

  1994cited by this paper
• Direct demonstration of three different states of the pancreatic cholecystokinin receptor.

  1994cited by this paper
• Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.

  1993cited by this paper
• Development of 1,4-benzodiazepine cholecystokinin type B antagonists.

  1993cited by this paper
• A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.

  1990cited by this paper
• Calibration of [14C]plastic standards for quantitative autoradiography of [125I]labeled ligands with Amersham Hyperfilm beta-max.

  1989cited by this paper
• Cholecystokinin and gastrin antagonists

  1989cited by this paper
• Calibration of [14C]plastic standards for quantitative autoradiography of [125I]labeled ligands with Amersham Hyperfilm β-max

  1989cited by this paper
• The use of 14C-labeled tissue paste standards for the calibration of 125I-labeled ligands in quantitative autoradiography.

  1987cited by this paper
• Crystallization-Induced Asymmetric Transformation: Stereospecific Synthesis of a Potent Peripheral CCK Antagonist

  1987cited by this paper
• Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.

  1986cited by this paper
• Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.

  1986cited by this paper
• Rat cardiac muscarinic receptors. I. Effects of guanine nucleotides on high- and low-affinity binding sites.

  1982cited by this paper
• Ligand: a versatile computerized approach for characterization of ligand-binding systems.

  1980cited by this paper

• Development and Validation of Novel Z-360-Based Macromolecules for the Active Targeting of CCK2-R.

  2024cites this paper
• Bromophenols from Symphyocladia latiuscula (Harvey) Yamada as Novel Cholecystokinin 2 Receptor Antagonists.

  2023cites this paper
• Cholecystokinin receptors in GtoPdb v.2023.1 Cholecystokinin receptors in GtoPdb v.2023.1

  2023cites this paper
• Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study

  2022cites this paper
• Cholecystokinin-2 receptor targeting with radiolabeled peptides: current status and future directions.

  2020cites this paper
• [ Tc]Tc-DGA1, a Promising CCK 2 R-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography

  2020cites this paper
• [99mTc]Tc-DGA1, a Promising CCK2R-Antagonist-Based Tracer for Tumor Diagnosis with SPECT.

  2020cites this paper
• Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor

  2019cites this paper
• Cholecystokinin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Targeting cholecystokinin‐2 receptor for pancreatic cancer chemoprevention

  2019cites this paper
• Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor.

  2016cites this paper
• Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.

  2015cites this paper
• Reversal of diastereoselectivity in the synthesis of peptidomimetic 3-carboxamide-1,4-benzodiazepin-5-ones.

  2015cites this paper
• Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.

  2015influential citation
• Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.

  2015cites this paper
• Development of a Highly Selective Allosteric Antagonist Radioligand for the Type 1 Cholecystokinin Receptor and Elucidation of Its Molecular Basis of Binding

  2015cites this paper
• Synthesis and Analgesic Activity of 3-Arylamino-1,2-Dihydro-3H-1,4-Benzodiazepin-2-Ones

  2015cites this paper
• Environment Wild Type Receptor in a High Cholesterol That Mimics the Dysfunction Observed for A Type 1 Cholecystokinin Receptor Mutant

  2014cites this paper
• A Type 1 Cholecystokinin Receptor Mutant That Mimics the Dysfunction Observed for Wild Type Receptor in a High Cholesterol Environment*

  2014cites this paper
• Application of Dimethylaminomethylene Ketone in Heterocycles Synthesis: Synthesis of 2‐(Isoxazolo, Pyrazolo, and Pyrimido) Substituted Analogs of 1,4‐Benzodiazepin‐5‐carboxamides Linked through an Oxyphenyl Bridge

  2014cites this paper
• Expedient Protocols for the Installation of 1,5‐Benzoazepino‐Based Privileged Templates on the 2‐Position of 1,4‐Benzodiazepine Through a Phenoxyl Spacer

  2014cites this paper
• A type 1 CCK receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment*

  2014cites this paper
• Application of chalcones in heterocycles synthesis: Synthesis of 2-(isoxazolo, pyrazolo and pyrimido) substituted analogues of 1,4-benzodiazepin-5-carboxamides linked through an oxyphenyl bridge

  2013cites this paper
• The Concise Guide to Pharmacology 2013/14: G Protein-Coupled Receptors

  2013cites this paper
• Molecular Basis for Benzodiazepine Agonist Action at the Type 1 Cholecystokinin Receptor*

  2013cites this paper
• Molecular Basis for Binding and Subtype Selectivity of 1,4-Benzodiazepine Antagonist Ligands of the Cholecystokinin Receptor*

  2012cites this paper
• Gastrin Receptor Pharmacology

  2012cites this paper
• Preclinical Evaluation of Radiolabeled DOTA-Derivatized Cyclic Minigastrin Analogs for Targeting Cholecystokinin Receptor Expressing Malignancies

  2012cites this paper
• Fluorescence Polarization Screening for Allosteric Small Molecule Ligands of the Cholecystokinin Receptor

  2011cites this paper
• Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.

  2010cites this paper